Immunovative Therapies (Israel)

Recent papers from Immunovative Therapies (Israel)

1. Generating Patient-Specific Anti-Tumor Responses with Non-Genetically Altered ‘Off-the-Shelf’ Allogeneic Cell Therapy: Leveraging Allo-Incompatibility for In Situ VaccinationVaccines · 2026
2. Clinical translation of an immunomodulatory cell therapy that is designed to convert “cold” tumors to “hot”: A phase 2B trial in 3L MSS/pMMR metastatic colorectal cancerTranslational Oncology · 2026
3. A Virus-Agnostic Cellular Immunomodulatory Platform for Chronic Respiratory Disease: Restoring Immune Competence and Mitigating Exacerbations in the ElderlyVaccines · 2026
4. Allo-priming as a universal anti-viral vaccine: protecting elderly from current COVID-19 and any future unknown viral outbreakJournal of Translational Medicine · 2020
5. Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog treated with autologous, tumour-derived chaperone-rich cell lysate (CRCL) vaccineInternational Journal of Hyperthermia · 2013
6. Proteomic analyses of different human tumour-derived chaperone-rich cell lysate (CRCL) anti-cancer vaccines reveal antigen content and strong similarities amongst the vaccines along with a basis for CRCL's unique structure: CRCL vaccine proteome leads to unique structureInternational Journal of Hyperthermia · 2013
7. Th-1 Lymphocytes Induce Dendritic Cell Tumor Killing Activity by an IFN-γ–Dependent MechanismThe Journal of Immunology · 2011
8. Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemiaBlood · 2010